Dynamic Sonography of Hepatic Tumors

Tanaka, Sachiko; Ioka, Tatsuya; Oshikawa, Osamu; Hamada, Yusuke; Yoshioka, Fumi

doi:10.2214/ajr.177.4.1770799

Cited by 108 publications

(113 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a single well-demarcated nodule can be found anywhere in the liver. Because this type of lesion has normal liver components, CEUS shows the same enhancement pattern with respect to the normal liver in all phases and remains iso-enhanced [52] . In the arterial and venous phase the supplying and draining vessels can be imaged [76] .…”

Section: Focal Fatty Change and Focal Fatty Sparing Of Livermentioning

confidence: 90%

“…BUS may miss iso-echoic lesions and lesions smaller than 1 cm [50] . Many studies have confirmed the improvement in accuracy of CEUS in diagnosing MLC [40,51,52] . CEUS also improved the detection of miliary metastases (0.5-1 cm) [53] .…”

Section: A B Cmentioning

confidence: 91%

“…Therefore, at the beginning of the portal phase, the arterial enhancement fades and the entire hypovascular lesion becomes hypo-echoic. In the late phase, both hypovascular and hypervascular metastases invariably appear dark compared with the enhanced background of normal liver parenchyma ("black-hole sign") [52] . During this late phase, both portal and late-phase imaging markedly increase the contrast between the enhanced normal liver (Figure 3).…”

Section: A B Cmentioning

confidence: 99%

See 2 more Smart Citations

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Wong

Xu²,

Xie³

2009

WJR

View full text Add to dashboard Cite

Patients with liver cirrhosis are at increased risk of hepatocellular carcinoma (HCC). Conventional or baseline ultrasound (BUS) is often used as the first-line tool for HCC surveillance or detection, but the accuracy of BUS in HCC detection or differentiation from other focal liver lesions (FLLs) is limited. Contrast-enhanced ultrasound (CEUS) represents a recent revolution in the field of ultrasonography and it has become increasingly important in the detection and evaluation of FLLs. In CEUS, HCC typically exhibits arterial hyper-enhancement and portal-venous washout represented by hypoenhanced lesions in the portal venous and late phases. The detection rate of HCC was significantly higher with CEUS compared with BUS. Even regenerative or some dysplastic nodules may exhibit arterial hyperenhancement as they are differentiated from HCC by its iso-enhancing pattern in portal and late phases. The contrast-enhancement patterns of other different types of benign and malignant FLLs, as well as their detection rates with CEUS, were also discussed.

show abstract

Section: Focal Fatty Change and Focal Fatty Sparing Of Livermentioning

confidence: 90%

Section: A B Cmentioning

confidence: 91%

Section: A B Cmentioning

confidence: 99%

See 1 more Smart Citation

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Wong

Xu²,

Xie³

2009

WJR

View full text Add to dashboard Cite

show abstract

“…It should be stressed that preliminary studies reporting the sensitivity of the technique as around 95% [444][445][446][447] are irrelevant in this context, as they relate to characterisation (of known but unclassified nodules), rather than detection (of lesions that may or may not be present in a series of cirrhotic livers). One observational study has been published reporting the use of CEUS in a surveillance series; 448 however, the reference standard used to establish 'true' diagnoses (longterm follow-up, including biopsy and CT) was suboptimal.…”

Section: More Effective More Expensive Ultrasoundmentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

“…2 In a recent study using contrast-enhanced US, 7% of 60 hepatocellular carcinomas displayed no vascular signs because of their deep location. 3 Such technical limitations are overwhelming when thin, slow blood flow vessels inside nodules less than 2 cm have to be studied (54% of the focal lesions included in the report by Fracanzani et al had a diameter less than 2 cm). Injecting the US medium contrast, such as Levovist (Schering, Berlin, Germany), does not improve the visualization of the microvasculature because images from such examinations show extensive color blooming and saturation of the color box, artifacts that are exceedingly prominent if the fundamental (conventional) harmonic is used, as Fracanzani et al did.…”

Section: Liver Nodule and Us Medium Contrast Agents: Past And Futurementioning

confidence: 99%

Liver nodule and US medium contrast agents: Past and future

Francica¹,

Giorgio²

2002

Hepatology

View full text Add to dashboard Cite

Dynamic Sonography of Hepatic Tumors

Abstract: Dynamic sonography in a protocol combining pulse inversion harmonic imaging and an IV bolus injection of the contrast agent proved to be an effective tool in characterizing liver tumors.

Cited by 108 publications

References 24 publications

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Liver nodule and US medium contrast agents: Past and future

Contact Info

Product

Resources

About